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Summary
This report describes transplantation of liver allograft from a circulatory death
donor who was supported by veno-venous extracorporeal membrane oxygenation
(ECMO) for 14 days and presented with severely altered liver functions. Success-
ful liver transplant was done in a patient with hepatocellular carcinoma (HCC) in
the background of primary sclerosing cholangitis. There was immediate graft
function and uneventful recovery with stable graft function at 1-year follow-up.
This case illustrates the ability of veno-venous ECMO to resuscitate organs in the
presence of severe dysfunction, and perhaps, lessons from this case may be incor-
porated to optimize the condition of organs rescued from these marginal donors
and exemplify the use of ECMO in normothermic regional perfusion in donors
after circulatory death.
Introduction
Liver transplantation is superior to any other treatment for
those with end-stage liver disease or primary liver tumours.
Despite the increased transplant activity worldwide, short-
age of donor organs remains a problem. Thus, surgeons
have resorted to accept marginal donor organs in an
attempt to increase the donor pool [1]. Liver dysfunction
of donor is usually considered relative contraindication [2];
however, consideration of such grafts with caution allows
expansion of donor pool without compromising post-
transplant outcome. In the absence of universal acceptance
criteria for donors with abnormal liver biochemistry, sur-
geons consider these by case-by-case basis [3]. One set lab-
oratory data is usually not sufficient to predict the graft
function, whereas ‘trend’ of such results provides a global
picture of the donor suitability.
The presented case herein is an example of a donor ini-
tially presented with highly abnormal organ function prior
to the donation. This donor was deemed unsuitable by all
other centres. Careful analysis of the donor history revealed
improved liver biochemistry while the patient was managed
on extracorporeal membrane oxygenation (ECMO) sup-
port. Through this manuscript, we aim to report the first
case in the literature thus far on successful use of a liver
graft from donors after circulatory death (DCD) donor
maintained on veno-venous ECMO. This will be discussed
in the background rationale for graft acceptance and recipi-
ent selection and successful outcomes. It is estimated that
treatment is withdrawn in many patients maintained on
ECMO annually in the UK and other countries although an
exact figure is difficult to predict [4,5]. Careful selection
may help utilize some of the organs from these donors and
contribute to ease the pressure on transplant wait lists.
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Case report
Donor history
A 35-year-old patient (54 kg, blood group O) with 2-year
history of idiopathic pulmonary fibrosis and awaiting lung
transplantation was admitted to the local hospital with
recurrent pneumocystis pneumonia. Patient was appropri-
ately treated with antibiotics, and on the 6th day of admis-
sion, patient developed acute respiratory failure secondary
to underlying pulmonary fibrosis. This patient was com-
menced on veno-venous ECMO; meanwhile, cardiac arrest
occurred on the 7th day of admission secondary to a pneu-
mothorax. Although successfully resuscitated, the patient
was deemed medically unsuitable for lung transplant. Fur-
ther treatment was deemed futile. Patient was maintained
on veno-venous ECMO until the option of organ donation
was explored.
Subsequent to cardiac arrest, donor liver function
showed high alanine aminotransferase (ALT) >3000 U/l,
which progressively improved to 229 U/l the day before
organ offering. Immediate preprocurement donor ALT,
alkaline phosphatase and bilirubin were 97 U/l, 172 U/l
and 20 lM, respectively. Patient maintained core body tem-
perature of 36.4 °C and oxygen saturation 99% through
ECMO support. There was continuous infusion of ino-
tropes. The organ offer was declined by other centres pri-
marily due to liver dysfunction evident from laboratory
results. When offered, careful review of the history and the
laboratory data convinced us the improving liver function
while the patient was on ECMO. The extracorporeal oxy-
genation was considered a reassurance; hence, the organ
offer was accepted.
Donor treatment withdrawal entailed discontinuation of
ECMO support, inotropes and extubation. Circulatory
death ensued soon after treatment withdrawal, and the
donor warm ischaemia time was 32 min. Organs were
recovered in the modified super-rapid technique. Univer-
sity of Wisconsin (UW) solution was used for organ preser-
vation. A soft, well-perfused liver graft was procured that
showed normal anatomy, no steatosis or injuries. Graft
weight was 1203 g.
Recipient
The unit adopts a policy of allocating high-risk organs to
recipients without advanced liver disease. Thus, a 59-year-
old patient with hepatocellular carcinoma in the back-
ground of primary sclerosing cholangitis was selected. The
recipient operation was standard. Total cold ischaemia time
was 06:15 hours. Implantation time was 28 min with total
operative time of 05:40 hours. There was no evidence of
postreperfusion syndrome during the reperfusion, and
patient remained stable throughout the operation. No
packed red blood cell or plasma was given intraoperatively,
and final haemoglobin at the time of closure was 9.8 g/dl.
Immediate post-operative recovery was excellent. Aspartate
transaminase and ALT peaked at 549 and 884 U/l, respec-
tively, following transplantation (Fig. 1). He was diagnosed
with acute cellular rejection on day 5 and successfully trea-
ted with pulsed steroids. All graft functions were normal-
ized at 14 days following transplantation, and patient now
completes 1 year with stable graft function.
Discussion
Shortage of donor organs has been largely contributed by
expanding the criteria, and indications for transplantation
and marginal grafts are widely used in this background.
Through ‘utilitarian approach’ practised in our unit, ideal
donor–recipient matching could be performed when mar-
ginal grafts are used. Blood group-O-recipients at present
face fierce competition for organs, and current wait times
for a deceased donor graft in the UK for such recipients is
199 days [6]. Nearly 20% of these drop out due to disease
progression, tumour growth or medically unsuitable for
transplantation [7]. Therefore, any blood group-O-donor
could be considered a potential resource unless proven
otherwise. The advantage of utilizing the marginal organs
in a utilitarian approach is the less competition it creates
for those remaining on the wait list when a suitable, ideal
quality graft becomes available.
Use of liver grafts from donors with abnormal liver bio-
chemistry is not a new concept. Liver grafts with altered
liver functions offer survival chance for many patients and
help reduce mortality and dropout on the waiting lists [8].
Of 388 liver transplant recipients who received grafts from
extended criteria donors, 20.5% were from donors with
raised liver function tests, yet outcomes were comparable
Figure 1 Trends of serum alanine aminotransferase (ALT) (predona-
tion) and recipient serum ALT post-transplant.
© 2014 Steunstichting ESOT 27 (2014) e50–e53 e51
Mourad et al. Organ donor supported by ECMO
with standard donors [8]. Therefore, the previously consid-
ered relative contraindication to use grafts from those with
abnormal liver biochemistry is currently revisited by many
centres.
The successful use of liver graft from the donor pre-
sented herein is attributable to ECMO. Considerable
period of artificial oxygenation allowed the ischaemic
insult to the liver from cardiac arrest to recover. ECMO
is generally used as arterio-venous ECMO for both car-
diac and respiratory support or as veno-venous ECMO,
which only support oxygenation of tissues [9]. It has
been demonstrated that pulsatile blood flow was of con-
siderable importance to hepatic and renal function with
more efficient perfusion [10]. In this donor, ECMO
maintained efficient perfusion and oxygenation of poten-
tially transplantable organs.
Johnson et al. [11] reported first ever liver transplant
from a donor who was maintained on veno-venous ECMO
for 29 days, and this was a donation after brain death
(DBD) where there was no warm ischaemia involved, and
presented case is the first successful use of a liver graft from
DCD donor maintained on veno-venous ECMO; predona-
tion ECMO provided the reassurance to use this graft, and
this decision was influenced by recent interest on applica-
tion of ECMO as bridge to organ donation between asys-
tole and procurement, reversing anaerobic metabolism
mimicking a period of ischaemic preconditioning [12]. In a
previously reported DCD donor, however, arterio-venous
ECMO had been successfully used, albeit for a much
shorter duration. ECMO permits the assessment of donor
organs under nonischaemic conditions over a period of
time through biochemical means, reflecting the ability of
liver graft to recover from warm ischaemic injury in Maas-
tricht category II DCD donors [13] (Table 1). This princi-
ple was recently introduced in the UK in Maastricht
category III DCD donors by some groups, including
author’s institution using a modified organ procurement
protocol [19] in the form of regional perfusion involving
abdominal compartment (normothermic regional perfu-
sion – NRP). A recent systemic review consolidated the evi-
dence for regional organ perfusion with ECMO of DCD
organs from ischaemic injury and enables transplantation
with acceptable survival [20]. Although NRP protocols rec-
ommend shorter period of organ perfusion than the longer
use of ECMO in the presented case, the lessons from this
case may probably help justify the use of NRP in DCD
donors.
In summary, we present the first successful use of liver
graft from a DCD donor with significantly altered bio-
chemistry and maintained on veno-venous ECMO. Organ
functions improved while maintained on ECMO prior to
donation, and the clinical sequelae following transplanta-
tion was parallel with that of any standard liver transplant.
In the era of organ shortage, consideration of those main-
tained on ECMO for a considerable time period before
treatment is withdrawn may add few extra organs to the
donor pool.
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Table 1. The use of ECMO in the different literatures to support liver grafts prior to organ harvest.
Timing of ECMO Type of ECMO Donor type
Number of
cases Outcomes
Prior to death (predonation) Arterio-venous DCD [14] 1 Excellent immediate function, 2-year follow-up
Veno-venous DBD [11] 1 Excellent immediate function, follow-up N/A






DCD (II)† [15] 34 (8.5%)‡ 82% 1-year overall survival/70% 1-year graft survival
DCD (II) [16] 20 (46.5%) 85% 1-year overall survival/80% 1-year graft survival
DCD (II) [17] 14 (N/A) 71% 1-year overall survival/43% 1-year graft survival
DCD (III)† [18] 12 (63%) 91% 1-year overall survival/91% 1-year graft survival
DCD, donors after circulatory death; ECMO, extracorporeal membrane oxygenation; N/A, not available.
*Presented case in this report.
†Maastricht category II and III DCD.
‡Percentage of successful liver graft procurement using ECMO in relation to the total number of potential donors.
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